This was consistent with a previous study, in which TP53 was mutated in 23.8% of aggressive B-cell lymphoma, and mutated TP53 could serve as an adverse independent predictor for PFS (43). Here, TP53 is linked to B-cell non-Hodgkin lymphoma.